| Cas number | 4052-13-5 |
|---|---|
| Pubchem | 10675 |
| Chemspiderid | 10225 |
| Unii | 8FP5Y6U39R |
| Chembl | 2110792 |
| Iupac name | 3-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-1H-quinazoline-2,4-dione |
| C | 21 |
| H | 23 |
| Cl | 1 |
| N | 4 |
| O | 2 |
| Smiles | C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC(=CC=C4)Cl |
| Stdinchi | 1S/C21H23ClN4O2/c22-16-5-3-6-17(15-16)25-13-11-24(12-14-25)9-4-10-26-20(27)18-7-1-2-8-19(18)23-21(26)28/h1-3,5-8,15H,4,9-14H2,(H,23,28) |
| Stdinchikey | FXZJKVODWNYPKK-UHFFFAOYSA-N |
Cloperidone is a quinazolinedione derivative first reported in 1965 by Miles Laboratories, notable for its sedative and antihypertensive properties.[1][2] Its pharmacological activity has been demonstrated in various animal models, including behavioral studies in dogs and cats, as well as motor coordination and locomotor activity assays in mice.[2] Cloperidone is not an approved drug and appears to remain an experimental compound with no current clinical use.[2]
References
- ^ Hayao S, Havera HJ, Strycker WG, Leipzig TJ, Kulp RA, Hartzler HE (November 1965). "New sedative and hypotensive 3-substituted 2,4(1H,3H)-quinazolinediones". Journal of Medicinal Chemistry. 8 (6): 807–815. doi:10.1021/jm00330a017. PMID 5885076
- ^ "Cloperidone hydrochloride". Inxight Drugs. NCATS. Retrieved 8 June 2025.